156 related articles for article (PubMed ID: 22927483)
1. Ontogeny and sorafenib metabolism.
Zimmerman EI; Roberts JL; Li L; Finkelstein D; Gibson A; Chaudhry AS; Schuetz EG; Rubnitz JE; Inaba H; Baker SD
Clin Cancer Res; 2012 Oct; 18(20):5788-95. PubMed ID: 22927483
[TBL] [Abstract][Full Text] [Related]
2. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.
Edginton AN; Zimmerman EI; Vasilyeva A; Baker SD; Panetta JC
Cancer Chemother Pharmacol; 2016 May; 77(5):1039-52. PubMed ID: 27053087
[TBL] [Abstract][Full Text] [Related]
5. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
Uldrick TS; Gonçalves PH; Wyvill KM; Peer CJ; Bernstein W; Aleman K; Polizzotto MN; Venzon D; Steinberg SM; Marshall V; Whitby D; Little RF; Wright JJ; Rudek MA; Figg WD; Yarchoan R
Oncologist; 2017 May; 22(5):505-e49. PubMed ID: 28341759
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
Ye L; Yang X; Guo E; Chen W; Lu L; Wang Y; Peng X; Yan T; Zhou F; Liu Z
PLoS One; 2014; 9(5):e96664. PubMed ID: 24797816
[TBL] [Abstract][Full Text] [Related]
8. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
Yanni SB; Annaert PP; Augustijns P; Ibrahim JG; Benjamin DK; Thakker DR
Drug Metab Dispos; 2010 Jan; 38(1):25-31. PubMed ID: 19841059
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7.
Godamudunage MP; Grech AM; Scott EE
Drug Metab Dispos; 2018 Sep; 46(9):1329-1337. PubMed ID: 29991575
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Lathia C; Lettieri J; Cihon F; Gallentine M; Radtke M; Sundaresan P
Cancer Chemother Pharmacol; 2006 May; 57(5):685-92. PubMed ID: 16133532
[TBL] [Abstract][Full Text] [Related]
12. [Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].
Wang J; Lü BH; Dai XJ; Zhang YF; Chen XY; Zhong DF
Yao Xue Xue Bao; 2017 Mar; 52(3):443-8. PubMed ID: 29979858
[TBL] [Abstract][Full Text] [Related]
13. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Gomo C; Coriat R; Faivre L; Mir O; Ropert S; Billemont B; Dauphin A; Tod M; Goldwasser F; Blanchet B
Invest New Drugs; 2011 Dec; 29(6):1511-4. PubMed ID: 20706860
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Noda S; Shioya M; Hira D; Fujiyama Y; Morita SY; Terada T
Cancer Chemother Pharmacol; 2013 Jul; 72(1):269-72. PubMed ID: 23673446
[TBL] [Abstract][Full Text] [Related]
17. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R
Xenobiotica; 2012 May; 42(5):409-16. PubMed ID: 22106961
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
20. Biological evaluation of a novel sorafenib analogue, t-CUPM.
Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
